Evidence map›Paper›PMID 24826058›Full record

ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2014

A preliminary report on adjuvant analgesic efficacy of HANS in opioid tolerant patients with cancer pain.

Xiaomei Li, Jianhua Zhu, Pingping Li, Guangqing Zhu, Xiaoming Wu, Huoming Chen, Huixia Zhao, Wei Wang, Ying Zhang, Wenhua Xiao and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Xiaomei Li1 Department of Medical Oncology, the First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China ; 2 Department of No.3 Cadre Ward; Expert Group, Beijing Army General Hospital, Beijing 100700, China ; 3 Key Laboratory of Carcinogenesis and Traditional Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China ; 4 Department of Medical Oncology, the General Hospital of the Air Force of the Chinese PLA, Beijing 100142, China ; 5 Integrated Department, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing 100021, China ; 6 Department of Medical Oncology, the Second Artillery General Hospital, Beijing 100088, China.
Jianhua Zhu1 Department of Medical Oncology, the First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China ; 2 Department of No.3 Cadre Ward; Expert Group, Beijing Army General Hospital, Beijing 100700, China ; 3 Key Laboratory of Carcinogenesis and Traditional Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China ; 4 Department of Medical Oncology, the General Hospital of the Air Force of the Chinese PLA, Beijing 100142, China ; 5 Integrated Department, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing 100021, China ; 6 Department of Medical Oncology, the Second Artillery General Hospital, Beijing 100088, China.
Pingping Li1 Department of Medical Oncology, the First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China ; 2 Department of No.3 Cadre Ward; Expert Group, Beijing Army General Hospital, Beijing 100700, China ; 3 Key Laboratory of Carcinogenesis and Traditional Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China ; 4 Department of Medical Oncology, the General Hospital of the Air Force of the Chinese PLA, Beijing 100142, China ; 5 Integrated Department, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing 100021, China ; 6 Department of Medical Oncology, the Second Artillery General Hospital, Beijing 100088, China.
Guangqing Zhu1 Department of Medical Oncology, the First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China ; 2 Department of No.3 Cadre Ward; Expert Group, Beijing Army General Hospital, Beijing 100700, China ; 3 Key Laboratory of Carcinogenesis and Traditional Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China ; 4 Department of Medical Oncology, the General Hospital of the Air Force of the Chinese PLA, Beijing 100142, China ; 5 Integrated Department, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing 100021, China ; 6 Department of Medical Oncology, the Second Artillery General Hospital, Beijing 100088, China.
Xiaoming Wu1 Department of Medical Oncology, the First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China ; 2 Department of No.3 Cadre Ward; Expert Group, Beijing Army General Hospital, Beijing 100700, China ; 3 Key Laboratory of Carcinogenesis and Traditional Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China ; 4 Department of Medical Oncology, the General Hospital of the Air Force of the Chinese PLA, Beijing 100142, China ; 5 Integrated Department, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing 100021, China ; 6 Department of Medical Oncology, the Second Artillery General Hospital, Beijing 100088, China.
Huoming Chen1 Department of Medical Oncology, the First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China ; 2 Department of No.3 Cadre Ward; Expert Group, Beijing Army General Hospital, Beijing 100700, China ; 3 Key Laboratory of Carcinogenesis and Traditional Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China ; 4 Department of Medical Oncology, the General Hospital of the Air Force of the Chinese PLA, Beijing 100142, China ; 5 Integrated Department, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing 100021, China ; 6 Department of Medical Oncology, the Second Artillery General Hospital, Beijing 100088, China.
Huixia Zhao1 Department of Medical Oncology, the First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China ; 2 Department of No.3 Cadre Ward; Expert Group, Beijing Army General Hospital, Beijing 100700, China ; 3 Key Laboratory of Carcinogenesis and Traditional Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China ; 4 Department of Medical Oncology, the General Hospital of the Air Force of the Chinese PLA, Beijing 100142, China ; 5 Integrated Department, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing 100021, China ; 6 Department of Medical Oncology, the Second Artillery General Hospital, Beijing 100088, China.
Wei Wang1 Department of Medical Oncology, the First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China ; 2 Department of No.3 Cadre Ward; Expert Group, Beijing Army General Hospital, Beijing 100700, China ; 3 Key Laboratory of Carcinogenesis and Traditional Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China ; 4 Department of Medical Oncology, the General Hospital of the Air Force of the Chinese PLA, Beijing 100142, China ; 5 Integrated Department, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing 100021, China ; 6 Department of Medical Oncology, the Second Artillery General Hospital, Beijing 100088, China.
Ying Zhang1 Department of Medical Oncology, the First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China ; 2 Department of No.3 Cadre Ward; Expert Group, Beijing Army General Hospital, Beijing 100700, China ; 3 Key Laboratory of Carcinogenesis and Traditional Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China ; 4 Department of Medical Oncology, the General Hospital of the Air Force of the Chinese PLA, Beijing 100142, China ; 5 Integrated Department, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing 100021, China ; 6 Department of Medical Oncology, the Second Artillery General Hospital, Beijing 100088, China.
Wenhua Xiao1 Department of Medical Oncology, the First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China ; 2 Department of No.3 Cadre Ward; Expert Group, Beijing Army General Hospital, Beijing 100700, China ; 3 Key Laboratory of Carcinogenesis and Traditional Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China ; 4 Department of Medical Oncology, the General Hospital of the Air Force of the Chinese PLA, Beijing 100142, China ; 5 Integrated Department, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing 100021, China ; 6 Department of Medical Oncology, the Second Artillery General Hospital, Beijing 100088, China.
Duanqi Liu1 Department of Medical Oncology, the First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China ; 2 Department of No.3 Cadre Ward; Expert Group, Beijing Army General Hospital, Beijing 100700, China ; 3 Key Laboratory of Carcinogenesis and Traditional Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China ; 4 Department of Medical Oncology, the General Hospital of the Air Force of the Chinese PLA, Beijing 100142, China ; 5 Integrated Department, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing 100021, China ; 6 Department of Medical Oncology, the Second Artillery General Hospital, Beijing 100088, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo observe the adjuvant analgesic efficacy of Han's Acupoint Nerve Stimulator (HANS) in opioid tolerant patients with cancer pain.

methodsA prospective non-controlled study was conducted. Opioid tolerant patients with cancer pain were enrolled and treated with both routinely analgesics and adjuvant HANS (2/100 Hz for 30 min/d, 5 d on and 2 d off for two weeks). Cancer pain, quality of life (QOL), anxiety and depression were assessed before enrollment and on d 8 and d 15 with the BPI-C, EORTC QLQ-C30, and self-rating anxiety scale (SAS)/self-rating depression scale (SDS), respectively; the therapeutic frequency of breakthrough pain (BP) and daily opioid dose were also recorded.

resultsTotally 47 patients meeting the inclusion criteria participated in this study; 43 patients completed the two-week treatment and assessment. The mean scores of patient's "worst" and "least" pain intensity assessed with BPI-C decreased significantly on d 8 and d 15; the therapeutic frequency of BP also significantly decreased; but the average daily dose of opioids did not change significantly. For the nine symptoms in EORTC QLQ-C30 assessment, the mean scores of pain, fatigue, constipation and insomnia were significantly lower on d 8 and d 15 compared with baseline; the mean scores of the overall health status, nausea/vomiting and the incidence rates of both anxiety and depression also decreased significantly on d 15.

conclusionsTo opioid tolerant patients with cancer pain, adjuvant treatment with HANS could improve pain release and patients' QOL by decreasing the severity of pain, fatigue, constipation, insomnia and other concomitant symptoms; it could also decrease the incidence rates of anxiety and depression.

Indexed as

Cancer painHan’s Acupoint Nerve Stimulator (HANS)opioid tolerance

Identifiers

PMID24826058
PMCPMC4000901
OpenAlexW2123604612

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.